Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Justin Hayes

Nurse Practitioner, Family Morgantown, WV Nurse Practitioner

NPI 1740715408 CMS profile 10751107

1 Medical Center Dr, Morgantown, WV 26506

Open in the dashboard

General payments

$12,381

713 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Hayes of Morgantown, WV is reported in the CMS Open Payments database as having received $12,381 across 713 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,653 143
2024 General $2,104 110
2023 General $2,007 126
2022 General $2,934 175
2021 General $2,683 159

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Hayes
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Justin Hayes were reported at $2,653. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Justin Hayes Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,683 $124 $35–$379 $132
2022 $2,934 $141 $44–$430 $149
2023 $2,007 $154 $49–$476 $160
2024 $2,104 $165 $51–$504 $164
2025 $2,653 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $2,884 177 payments
  2. Abbott Laboratories $1,314 87 payments
  3. Lilly USA, LLC $999 54 payments
  4. Amgen Inc. $814 44 payments
  5. AstraZeneca Pharmaceuticals LP $743 47 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $646 41 payments
  7. Dexcom, Inc. $639 33 payments
  8. Sanofi-Aventis U.S. LLC $638 37 payments
  9. Xeris Pharmaceuticals, Inc. $593 30 payments
  10. Insulet Corporation $353 18 payments
  11. Other $2,759 145 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,381 713 payments
Products named General payments · program years 2021–2025
  1. Ozempic $2,095 125 payments
  2. RYBELSUS $1,927 121 payments
  3. FreeStyle Libre 3 $796 55 payments
  4. FARXIGA $743 47 payments
  5. EVENITY $560 29 payments
  6. TRADJENTA $473 29 payments
  7. Dexcom G6 Transmitter $469 23 payments
  8. SOLIQUA 100/33 $458 28 payments
  9. Wegovy $416 26 payments
  10. FreeStyle Libre $413 25 payments
  11. Other $7,259 399 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

4,150

Median for Nurse Practitioner: 389

Drug cost

$3,772,968

Median for Nurse Practitioner: $21,885

Branded share of claims

88.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 728 $1,288,154
Ozempic Semaglutide Brand 370 $678,977
Jardiance Empagliflozin Brand 187 $275,839
Tresiba Flextouch U-200 Insulin Degludec Brand 146 $212,939
Humalog Kwikpen U-200 Insulin Lispro Brand 49 $160,579
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 113 $147,235
Synjardy Xr Empagliflozin/Metformin Hcl Brand 102 $135,523
Tresiba Flextouch U-100 Insulin Degludec Brand 189 $135,417
Trulicity Dulaglutide Brand 65 $118,843
Farxiga Dapagliflozin Propanediol Brand 80 $78,737

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$47,411

Medicare's payments for the services billed

Medicare patients

194

Average age 69

Services billed

1,363

90 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 62%
Chronic kidney disease 45%
Ischemic heart disease 41%
Depression 30%
Heart failure 23%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
$263 370 —
RYBELSUS
$241 — —
Korlym
$146 — —
JARDIANCE
$143 187 —
RECORLEV
$122 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

713 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record